Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock

Peptides

Volumn 26, Issue 2, 2005, Pages 207-216

  Giacometti, Andrea ^a,e   Cirioni, Oscar ^a   Ghiselli, Roberto ^a   Orlando, Fiorenza ^b   Kamysz, Wojciech ^c   Rocchi, Marco ^d   D'Amato, Giuseppina ^a   Mocchegiani, Federico ^a   Silvestri, Carmela ^a   Łukasiak, Jerzy ^c   Saba, Vittorio ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF URBINO   (Italy)

^e University of Urbino Urbino Italy ^*  (Italy)

Author keywords

Antimicrobial peptides; Endotoxin; Lipopolysaccharide; Pexiganan; Sepsis

Indexed keywords

BETA LACTAM ANTIBIOTIC; ESCHERICHIA COLI ENDOTOXIN; IMIPENEM; ISOTONIC SOLUTION; LIPOPOLYSACCHARIDE; MAGAININ DERIVATIVE; PEXIGANAN; PIPERACILLIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; CECUM; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG USE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; INJECTION; LETHALITY; LIGATION; LIQUID; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUNCTURE; RAT; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CECUM; DRUG THERAPY, COMBINATION; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; IMIPENEM; INJECTIONS, INTRAPERITONEAL; LIMULUS TEST; LIPOPOLYSACCHARIDES; MALE; PIPERACILLIN; POLYMYXIN B; RATS; RATS, WISTAR; SHOCK, SEPTIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; RATTUS NORVEGICUS;

EID: 19944391546     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2004.09.012     Document Type: Article

References (44)

1. S. Akashi, S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, and Y. Nagai Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14 J Exp Med 198 2003 1035 1042
2. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303 1310
3. P.Y. Bochud, and T. Calandra Pathogenesis of sepsis: new concepts and implications for future treatment Br Med J 326 2003 262 266
4. H.G. Boman Peptide antibiotics and their role in innate immunity Ann Rev Immunol 13 1995 61 92
5. R.C. Bone Pathophysiology of sepsis Ann Intern Med 115 1991 457 469
6. B. Byl, P. Clevenbergh, A. Kentos, F. Jacobs, A. Marchant, and J.L. Vincent Ceftazidime- and imipenem-induced endotoxin release during treatment of Gram-negative infections Eur J Clin Microbiol Infect Dis 20 2001 804 807
7. M. Cannon A family of wound healers Nature 328 1987 478
8. T. Christensen Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil Acta Chem Scand Ser B (Org Chem Biochem) 33 1979 763 776
9. J. Cohen, and J.S. McConnell Antibiotic-induced endotoxin release Lancet ii 1985 1069 1070
10. D.J. Diekema, M.A. Pfaller, R.N. Jones, G.V. Doern, P.L. Winokur, and A.C. Gales Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997 Clin Infect Dis 29 1999 595 607
11. J.J. Drabick, A.K. Bhattacharjee, D.L. Hoover, G.E. Siber, V.E. Morales, and L.D. Young Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent Antimicrob Agents Chemother 42 1998 583 588
12. H. Dupont, C. Carbon, J. Carlet The severe generalized peritonitis study group Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial Antimicrob Agents Chemother 44 2000 2028 2033
13. J.D. Edgeworth, D.F. Treacher, and S.J. Eykyn A 25-year study of nosocomial bacteremia in an adult intensive care unit Crit Care Med 27 1999 1421 1428
14. G.M. Eliopoulos, and R.C. Moellering Jr. Antimicrobial combinations V. Loria Antibiotics in laboratory medicine 1991 Williams & Wilkins Baltimore, MD 432 444
15. G.B. Fields, and R.L. Noble Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids Int J Pept Protein Res 35 1990 161 214
16. P.C. Fuchs, A.L. Barry, and S.D. Brown In vitro antimicrobial activity of MSI-78, a mainin analog Antimicrob Agents Chemother 42 1998 1213 1216
17. Y. Ge, D. MacDonald, K.J. Holroyd, C. Thornsberry, H. Wexler, and M. Zasloff In vitro antibacterial properties of pexiganan, an analog of magainin Antimicrob Agents Chemother 43 1999 782 788
18. A. Giacometti, O. Cirioni, F. Barchiesi, M.S. Del Prete, and G. Scalise Antimicrobial activity of polycationic peptides Peptides 20 1999 1265 1273
19. A. Giacometti, O. Cirioni, R. Ghiselli, F. Mocchegiani, G. D'Amato, and M.S. Del Prete Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats Gut 52 2003 874 878
20. A. Giacometti, O. Cirioni, G. Greganti, M. Quarta, and G. Scalise In vitro activity of membrane-active peptides against Gram-positive and Gram-negative aerobic bacteria Antimicrob Agents Chemother 42 1998 3320 3324
21. M.P. Glauser, G. Zanetti, J.D. Baumgartner, and J. Cohen Septic shock: pathogenesis Lancet 338 1991 732 736
22. M. Gough, R.E.W. Hancock, and N.M. Kelly Antiendotoxin activity of cationic peptide antimicrobial agents Infect Immun 64 1996 4922 4927
23. C.E. Hack, L.A. Aarden, and L.G. Thijs Role of cytokines in sepsis Adv Immunol 66 1997 101 195
24. R.E.W. Hancock Cationic peptides: effectors in innate immunity and novel antimicrobials Lancet Infect Dis 1 2001 156 164
25. R.E.W. Hancock, and M.G. Scott The role of antimicrobial peptides in animal defenses Proc Natl Acad Sci USA 97 2000 8856 8861
26. R.M. Hardaway A review of septic shock Am Surg 66 2000 22 29
27. C. Jaccard, N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, and R. Schneider Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis Antimicrob Agents Chemother 42 1998 2966 2972
28. O. Levy Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents Blood 96 2000 2664 2672
29. S. Manocha, D. Feinstein, A. Kumar, and A. Kumar Novel therapies for sepsis: antiendotoxin therapies Exp Opin Invest Drugs 11 2002 1795 1812
30. National committee for clinical laboratory standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6: Villanova, PA; 2003.
31. A.B. Onderdonk, W.M. Weinstein, N.M. Sullivan, J.G. Bartlett, and S.L. Gorbach Experimental intraabdominal abscesses in rats: quantitative bacteriology of infected animals Infect Immun 13 1974 22 26
32. S.J. Parker, and P.E. Watkins Experimental models of Gram-negative sepsis Br J Surg 88 2000 22 30
33. J.M. Prins, E.J. Kuijper, M.L.C.M. Mevissen, P. Speelman, and S.J.H. van Deventer Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum Infect Immun 63 1985 2236 2242
34. D.G. Remick, D.E. Newcomb, G.L. Bolgos, and D.R. Call Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture Shock 13 2000 110 116
35. B. Ruiz-Perez, R.L. Cisneros, T. Matsumoto, R.J. Miller, G. Vasios, and P. Calias Protection against lethal intra-abdominal sepsis by 1-(3-dimethylaminopropyl)-3-ethylurea J Infect Dis 188 2003 378 387
36. V.K. Sharma, and R.P. Dellinger Recent developments in the treatment of sepsis Exp Opin Invest Drugs 12 2003 139 152
37. J.L. Shenep, R.P. Barton, and K. Mogan Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental Gram-negative bacterial sepsis J Infect Dis 151 1985 1012 1018
38. K.J. Tracey, and E. Abraham From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Shock 11 1999 224 225
39. R.J. Ulevitch, and P.S. Tobias Recognition of Gram-negative bacteria and endotoxin by the innate system Curr Opin Immunol 11 1999 19 22
40. R.P. Wenzel, M.R. Pinsky, R.J. Ulevitch, and L. Young Current understanding of sepsis Clin Infect Dis 22 1996 407 413
41. A.P. Wheeler, and G.R. Bernard Treating patients with severe sepsis N Engl J Med 340 1999 207 214
42. J.A. Yethon, and C. Whitfield Lipopolysaccharide as a target for the development of novel therapeutics in Gram-negative bacteria Curr Drug Targets Infect Disord 1 2001 91 106
43. M. Zasloff Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor Proc Natl Acad Sci USA 84 1987 5449 5453
44. E.J. Ziegler, C.J. Fisher, C.L. Sprung, R.C. Straube, J.C. Sadoff, G.E. Foulke The HA-1A sepsis study group Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin N Engl J Med 324 1991 429 436